In detail, promoting BECLIN1-dependent autophagy through the disruption of BECLIN-1/BCL-2 interaction—for instance, with venetoclax—could improve the chemotherapy response in refractory DLBCL, providing insights for the design of novel clinical trials that include autophagy inducers in the clinical management of this tumor. This evidence concerns the gene BECN1 and neoplasm.